Roland E. Knoblauch

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

28h-index4.4kcitations124works5.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(67), Sarcoma Diagnosis and Treatment(23), Colorectal Cancer Treatments and Studies(23), Lung Cancer Research Studies(19), Lung Cancer Diagnosis and Treatment(15)

Publications124 total

Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: the phase 1b PALOMA study
Clinical Lung Cancer·2026Open Access
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Journal of Clinical Oncology·2025Open Access
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Targeted Oncology·2025Open Access
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer·2025
Amivantamab Plus Chemotherapy in Japanese Patients With <scp>EGFR</scp> Exon 20 Insertions <scp>NSCLC</scp>
Cancer Science·2025Open Access
Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine·2025· 39 cited
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Journal of Thoracic Oncology·2025· 12 citedOpen Access
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
Lung Cancer·2025· 4 citedOpen Access
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Journal of Thoracic Oncology·2025· 16 citedOpen Access
Patient-Reported Outcomes and Time to Symptomatic Progression from Papillon: Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Egfr Exon 20 Insertion-Mutated Advanced Nsclc
SSRN Electronic Journal·2025Open Access
MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC
Journal of Thoracic Oncology·2024· 3 citedOpen Access
Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Cancer Research·2024· 1 cited
6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
ESMO Open·2024· 2 citedOpen Access
2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON
ESMO Open·2024· 1 citedOpen Access
7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC
ESMO Open·2024· 2 citedOpen Access
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
Journal of Clinical Oncology·2024· 8 cited
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
Journal of Clinical Oncology·2024· 8 cited
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study
Cancer Treatment and Research Communications·2024· 1 citedOpen Access
513MO Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis
Annals of Oncology·2023· 2 citedOpen Access
OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
Journal of Thoracic Oncology·2023· 14 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Byoung Chul Cho(26), Meena Thayu(19), Joshua Bauml(18), Alexander I. Spira(17), Joshua C. Curtin(15), Rachel E. Sanborn(14), Catherine A. Shu(13), Joshua K. Sabari(13), Amy Roshak(13), John Xie(12), Enriqueta Felip(11), Eric B. Haura(9), George D. Demetri(8), Margaret von Mehren(8), Shreyaskumar Patel(8), Nicolas Girard(8), Ji‐Youn Han(8), James Chih‐Hsin Yang(8), Robin L. Jones(7), Robert G. Maki(7)